Simpler HIV pill shows promise for teens in small trial

NCT ID NCT03682848

Completed Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 adolescents aged 12 to 17 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could control the virus as well as standard three-drug combinations, while potentially causing fewer long-term side effects. After 48 weeks, the main measure was the percentage of teens with undetectable virus levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dolutegravir/Lamivudine (DTG/3TC) fixed-dose combination pill
What this could lead to: If successful, this could offer a simpler, less toxic daily HIV treatment option for adolescents, reducing long-term side effects while keeping the virus under control.
What could go wrong: This is a small, single-arm study with only 32 participants, so results may not apply to all teens. HIV treatment must be taken lifelong, and the virus could still become resistant or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Kericho, 20200, Kenya
GSK Investigational Site

Kisumu, 40100, Kenya
GSK Investigational Site

Cape Town, 7500, South Africa
GSK Investigational Site

Durban, 4001, South Africa
GSK Investigational Site

Johannesburg, 1862, South Africa
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Bangkok, 10700, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.